XiaoMi-AI文件搜索系统
World File Search SystemForefront
Part the Cloud 2023 Impact Report
In a continued effort to be at the forefront of science, Part the Cloud has launched a new fundraising initiative — the Gene Targeting Challenge — to supercharge the development of therapies tailored to the genetic underpinnings of Alzheimer's disease. This challenge, which will support new and ongoing early-stage clinical trials using gene targeting, is what Part the Cloud does best: investing in big, bold ideas that will move the needle in our quest to end Alzheimer's and all other dementia. In this impact report, you'll read more about the new Gene Targeting Challenge, as well as Part the Cloud's current global impact on the Alzheimer's drug pipeline broadly.
Evolving Technologies Horizon Scan
This report is a first step in engaging colleagues in continuous, cross- cutting reflection around emerging and potential future trends and starting to consider how we might equip practitioners and experts with the tools to anticipate and tackle the ever-evolving challenges and opportunities children face in the digital world. As such efforts continue, further investment in a diverse portfolio of research initiatives that leverages the knowledge of technologists, investigators, trust and safety professionals, and other frontline experts stands to deliver significant returns. Critically, engaging with and learning from young people must be a central component of these efforts. Building with their perspectives and needs at the forefront will be vital to ensuring the next generation has access to the safe and vibrant digital world they deserve.
2024; 14(7): 2969-2992. doi: 10.7150/thno.96403 Review Actinium-225 targeted alpha particle therapy for prostate cancer
Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 ( 225 Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses. The development of radiolabeling techniques involving EDTA, DOTA, DOTPA, and Macropa chelators has laid the groundwork for advancements in this field. At the forefront of clinical trials with 225 Ac in PCa are PSMA-targeted TAT agents, notably [ 225 Ac]Ac-PSMA-617, [ 225 Ac]Ac-PSMA-I&T and [ 225 Ac]Ac-J591. Ongoing investigations spotlight [ 225 Ac]Ac-hu11B6, [ 225 Ac]Ac-YS5, and [ 225 Ac]Ac-SibuDAB, targeting hK2, CD46, and PSMA, respectively. Despite these efforts, hurdles in 225 Ac production, daughter redistribution, and a lack of suitable imaging techniques hinder the development of TAT. To address these challenges and additional advantages, researchers are exploring alpha-emitting isotopes including 227 Th, 223 Ra, 211 At, 213 Bi, 212 Pb or 149 Tb, providing viable alternatives for TAT.
ProGrass 技术表
• 仅在已建立的草地上使用，且草地已超过 12 个月大。• 为获得最佳效果，请将其应用于最佳生长期的健康、活跃生长的杂草。• 杂草必须没有病虫害；没有遭受霜冻、干旱、涝渍或营养缺乏。• ProGrass 是一种主要作用于叶面的除草剂，因此施用时不存在的杂草将无法得到控制。• 如果预计会出现霜冻或叶子潮湿，请勿喷洒，因为可能会发生径流。• 如果作物受到压力或施用后出现不利条件，草可能会略微变黄或短暂生长受到抑制，但会迅速消失，不会对草的产量和质量产生负面影响。• ProGrass 对三叶草和其他豆科植物不安全。• 不要将 ProGrass 用于草籽作物。• 使用硬水施用时，请考虑加入水质调节剂。• 如果放牧草中有蓟，请考虑使用 Forefront ® T。如果割下的草中有蓟，则 MCPA 在物理上是兼容的。使用风险自负 • 使用 ProGrass 后仅 7 天即可修剪草坪，非常适合：
